Trilab, LLC

Trilab, LLC was paid $19.27M by Medicaid between Jan 2018 and Dec 2024, across 78 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 43% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Illinois

Rank by total paid#10 of 235

Median peer was paid$123K

This provider vs. median157×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	12,507	$413K
2019	24,732	$1.42M
2020	33,453	$2.05M
2021	94,641	$4.76M
2022	52,160	$2.45M
2023	62,902	$2.84M
2024incomplete	97,242	$5.34M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	43%	90,165	43,268	$8.26M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	26%	137,474	60,876	$4.92M
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	8.8%	24,294	14,213	$1.70M
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	5.3%	16,821	6,920	$1.03M
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	4.0%	2,518	2,182	$769K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	2.6%	22,377	12,786	$505K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	1.2%	2,733	1,132	$230K
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	1.2%	7,119	5,995	$227K
87529		<1%	2,929	2,492	$172K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	2,358	1,806	$143K
86480		<1%	3,225	2,612	$128K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	1,042	844	$124K

66 more codes

G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source	<1%	5,115	$117K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	2,374	$102K
87641		<1%	3,098	$95K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	3,085	$94K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	3,079	$94K
87500		<1%	3,113	$68K
87625		<1%	2,762	$59K
87563		<1%	3,054	$56K
80053	Comprehensive metabolic panel	<1%	6,081	$47K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	822	$39K
87511		<1%	879	$30K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	1,412	$30K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	6,250	$27K
81514		<1%	158	$25K
86803		<1%	1,980	$23K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	2,234	$21K
87522	Neg quan hep c or qual rna	<1%	513	$18K
80074		<1%	665	$17K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	653	$14K
86706		<1%	1,029	$10K
86704		<1%	925	$10K
84443	Thyroid stimulating hormone (TSH)	<1%	770	$9K
87340		<1%	917	$8K
87653		<1%	252	$8K
80061	Lipid panel	<1%	1,406	$7K
83735		<1%	1,187	$6K
86592		<1%	1,956	$6K
87640		<1%	162	$5K
83036	Hemoglobin; glycosylated (A1C)	<1%	1,087	$5K
83719		<1%	632	$5K
84439		<1%	397	$3K
84481		<1%	252	$2K
81001		<1%	739	$2K
80048	Basic metabolic panel (calcium, ionized)	<1%	253	$2K
84702		<1%	187	$1K
81003		<1%	839	$1K
80335		<1%	109	$1K
80372		<1%	54	$939.96
80369		<1%	54	$939.96
87521	Neg quan hep c or qual rna	<1%	25	$899.34
80338		<1%	48	$889.95
82607		<1%	101	$866.46
80355		<1%	49	$753.84
80366		<1%	54	$660.21
87806		<1%	35	$561.67
80320		<1%	50	$139.81
83789		<1%	53	$118.95
36415	Collection of venous blood by venipuncture	<1%	2,761	$97.45
83992		0%	55	$0.00
80361		0%	48	$0.00
80348		0%	48	$0.00
80354		0%	49	$0.00
80346		0%	48	$0.00
80365		0%	54	$0.00
80356		0%	48	$0.00
80362		0%	51	$0.00
80345		0%	49	$0.00
80353		0%	49	$0.00
82541		0%	49	$0.00
80184		0%	49	$0.00
80349		0%	48	$0.00
80358		0%	61	$0.00
K1034	Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count	0%	24	$0.00
80359		0%	48	$0.00
80324		0%	48	$0.00
80371		0%	46	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialNASEERUDDIN, SAMEER (PARTNER)